Mediolanum International Funds Ltd Purchases 4,085 Shares of Bristol-Myers Squibb (NYSE:BMY)

Mediolanum International Funds Ltd increased its position in Bristol-Myers Squibb (NYSE:BMY) by 4.6% in the 4th quarter, Holdings Channel reports. The firm owned 92,612 shares of the biopharmaceutical company’s stock after buying an additional 4,085 shares during the quarter. Mediolanum International Funds Ltd’s holdings in Bristol-Myers Squibb were worth $5,179,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently bought and sold shares of the business. Sivik Global Healthcare LLC acquired a new stake in shares of Bristol-Myers Squibb during the 4th quarter valued at about $3,959,000. Crews Bank & Trust bought a new stake in shares of Bristol-Myers Squibb during the fourth quarter worth $335,000. Capital Investment Advisory Services LLC increased its holdings in shares of Bristol-Myers Squibb by 11.5% in the fourth quarter. Capital Investment Advisory Services LLC now owns 13,504 shares of the biopharmaceutical company’s stock valued at $764,000 after purchasing an additional 1,394 shares in the last quarter. Coston McIsaac & Partners raised its position in shares of Bristol-Myers Squibb by 12.7% during the fourth quarter. Coston McIsaac & Partners now owns 2,074 shares of the biopharmaceutical company’s stock worth $117,000 after acquiring an additional 233 shares during the last quarter. Finally, Westhampton Capital LLC raised its holdings in Bristol-Myers Squibb by 0.7% during the 4th quarter. Westhampton Capital LLC now owns 27,417 shares of the biopharmaceutical company’s stock worth $1,551,000 after purchasing an additional 200 shares during the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on BMY shares. Daiwa America upgraded Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a report on Wednesday, November 13th. Leerink Partnrs upgraded Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a report on Tuesday, November 12th. Daiwa Capital Markets raised shares of Bristol-Myers Squibb from a “neutral” rating to an “outperform” rating in a report on Wednesday, November 13th. UBS Group increased their price objective on shares of Bristol-Myers Squibb from $50.00 to $54.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 9th. Finally, Bank of America reiterated a “neutral” rating and issued a $63.00 target price on shares of Bristol-Myers Squibb in a research report on Tuesday, December 10th. Two research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, four have assigned a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $56.60.

Bristol-Myers Squibb Stock Performance

Shares of BMY opened at $58.86 on Friday. Bristol-Myers Squibb has a one year low of $39.35 and a one year high of $61.10. The company has a market cap of $119.38 billion, a PE ratio of -16.40, a P/E/G ratio of 2.10 and a beta of 0.45. The stock has a 50-day moving average of $57.60 and a 200-day moving average of $53.19. The company has a debt-to-equity ratio of 2.83, a current ratio of 1.24 and a quick ratio of 1.09.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported $1.80 EPS for the quarter, beating analysts’ consensus estimates of $1.49 by $0.31. Bristol-Myers Squibb had a positive return on equity of 11.94% and a negative net margin of 15.30%. The firm had revenue of $11.89 billion during the quarter, compared to analysts’ expectations of $11.26 billion. During the same quarter last year, the firm posted $2.00 earnings per share. The company’s revenue for the quarter was up 8.4% compared to the same quarter last year. On average, equities research analysts predict that Bristol-Myers Squibb will post 0.92 EPS for the current fiscal year.

Bristol-Myers Squibb Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, February 3rd. Shareholders of record on Friday, January 3rd will be paid a dividend of $0.62 per share. This represents a $2.48 dividend on an annualized basis and a yield of 4.21%. The ex-dividend date is Friday, January 3rd. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. Bristol-Myers Squibb’s payout ratio is -69.08%.

Insiders Place Their Bets

In other news, SVP Phil M. Holzer sold 700 shares of Bristol-Myers Squibb stock in a transaction dated Monday, November 4th. The shares were sold at an average price of $55.62, for a total transaction of $38,934.00. Following the completion of the transaction, the senior vice president now directly owns 11,760 shares in the company, valued at $654,091.20. This trade represents a 5.62 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.09% of the company’s stock.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.